DP2 receptor antagonists: Novel therapeutic target for COPD

Molecular and Cellular Pharmacology

Volumn 2, Issue 3, 2010, Pages 89-96

  Stebbins, Karin J ^a   Evans, Jilly F ^a   Lorrain, Daniel S ^a  

^a Amira Pharmaceuticals   (United States)

Author keywords

Cigarette smoke; COPD; CRTh2; DP2

Indexed keywords

AM 156; AM 206; ANTIINFLAMMATORY AGENT; AZD 1981; BRONCHODILATING AGENT; CORTICOSTEROID; DP2 RECEPTOR; DP2 RECEPTOR ANTAGONIST; G PROTEIN COUPLED RECEPTOR; LONG ACTING DRUG; PROSTAGLANDIN D2; RECEPTOR BLOCKING AGENT; ROFLUMILAST; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; DRUG MECHANISM; DRUG TARGETING; ENVIRONMENTAL EXPOSURE; EPITHELIUM HYPERPLASIA; HUMAN; INFLAMMATION; METAPLASIA; NONHUMAN; PATHOGENESIS; PROSTAGLANDIN SYNTHESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BLOCKING; RISK FACTOR; TH2 CELL; UNSPECIFIED SIDE EFFECT;

EID: 77954248655     PISSN: None     EISSN: 19381247     Source Type: Journal    
DOI: 10.4255/mcpharmacol.10.12     Document Type: Article

References (66)

1. Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med 1999;160:893-8.
2. Saetta M, Baraldo S, Corbino L, et al. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:711-7.
3. Groneberg DA, Chung KF. Models of chronic obstructive pulmonary disease. Respir Res 2004;5:18.
4. Corrigan CJ, Kay AB. The roles of inflammatory cells in the pathogenesis of asthma and of chronic obstructive pulmonary disease. Am Rev Respir Dis 1991;143(5 Pt 1):1165-8; discussion 75-6.
5. Saetta M. Airway inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160(5 Pt 2):S17-20.
6. Shapiro SD. Proteinases in chronic obstructive pulmonary disease. Biochem Soc Trans 2002;30:98-102.
7. Shapiro SD. The macrophage in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160(5 Pt 2):S29-32.
8. Cosio MG, Majo J. Inflammation of the airways and lung parenchyma in COPD: role of T cells. Chest. 2002;121(5 Suppl):160S-5S.
9. Stockley RA. Neutrophils and the pathogenesis of COPD. Chest 2002;121(5 Suppl):151S-5S.
10. Tetley TD. Macrophages and the pathogenesis of COPD. Chest 2002;121(5 Suppl):156S-9S.
11. Soler N, Ewig S, Torres A, Filella X, Gonzalez J, Zaubet A. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999;14:1015-22.
12. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153:530-4.
13. Yamamoto C, Yoneda T, Yoshikawa M, et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 1997;112:505-10.
14. Richwine L. US panel rejects Forest, Nycomed lung drug. Reuters 2010.
15. Hirschler B. EU agency backs Nycomed's Daxas after U.S. rebuff. Reuters 2010.
16. Urade Y, Ujihara M, Horiguchi Y, et al. Mast cells contain spleen-type prostaglandin D synthetase. J Biol Chem 1990;265:371-5.
17. Urade Y, Ujihara M, Horiguchi Y, Ikai K, Hayaishi O. The major source of endogenous prostaglandin D2 production is likely antigen-presenting cells. Localization of glutathione-requiring prostaglandin D synthetase in histiocytes, dendritic, and Kupffer cells in various rat tissues. J Immunol 1989;143:2982-9.
18. Tanaka K, Ogawa K, Sugamura K, Nakamura M, Takano S, Nagata K. Cutting edge: differential production of prostaglandin D2 by human helper T cell subsets. J Immunol 2000;164:2277-80.
19. Pettipher R, Hansel TT. Antagonists of the prostaglandin D2 receptor CRTH2. Drug News Perspect 2008;21:317-22.
20. Gosset P, Bureau F, Angeli V, et al. Prostaglandin D2 affects the maturation of human monocyte-derived dendritic cells: consequence on the polarization of naïve Th cells. J Immunol 2003;170:4943-52.
21. Shirasaki H, Kikuchi M, Kanaizumi E, Himi T. Accumulation of CRTH2-positive leukocytes in human allergic nasal mucosa. Ann Allergy Asthma Immunol 2009;102:110-5.
22. Nakajima T, Asano Y, Shiraishi Y, et al. Expression of PGD2 Receptor CRTH2 (DP2) on Human Lung Fibroblasts. J Allergy Clin Immunol 2005;115:S141.
23. Uller L, Ribbene A, Sammut D, Howarth P, Holgate S, Davies D. Up-regulation of epithelial and fibroblast prostaglandin D2 CRTH2-receptors in asthma. World Allergy Organization Journal 2007; 10.1097/01.WOX.0000301068.24143.93.
24. Chiba T, Kanda A, Ueki S, et al. Prostaglandin D2 induces IL-8 and GM-CSF by bronchial epithelial cells in a CRTH2-independent pathway. Int Arch Allergy Immunol 2006;141:300-7.
25. Sargent C, Stinson S, Schmidt J, et al. The effect of a selective CRTh2 antagonist on tobacco smoke (TS) induced airway inflammation and remodelling in the mouse. Proceedings of the British Pharmacological Society, 7th James Black Conference 2009;7:pA2 online.
26. Xue L, Gyles SL, Barrow A, Pettipher R. Inhibition of PI3K and calcineurin suppresses chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2)-dependent responses of Th2 lymphocytes to prostaglandin D(2). Biochem Pharmacol 2007;73:843-53.
27. Tirouvanziam R, Gernez Y, Conrad CK, et al. Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways. Proc Natl Acad Sci USA 2008;105:4335-9.
28. Abe H, Takeshita T, Nagata K, et al. Molecular cloning, chromosome mapping and characterization of the mouse CRTH2 gene, a putative member of the leukocyte chemoattractant receptor family. Gene 1999;227:71-7.
29. Chevalier E, Stock J, Fisher T, et al. Cutting edge: chemoattractant receptor-homologous molecule expressed on Th2 cells plays a restricting role on IL-5 production and eosinophil recruitment. J Immunol 2005;175:2056-60.
30. Takeshita K, Yamasaki T, Nagao K, et al. CRTH2 is a prominent effector in contact hypersensitivity-induced neutrophil inflammation. Int Immunol 2004;16:947-59.
31. Hata AN, Zent R, Breyer MD, Breyer RM. Expression and molecular pharmacology of the mouse CRTH2 receptor. J Pharmacol Exp Ther 2003;306:463-70.
32. Stebbins KJ, Broadhead AR, Baccei CS, et al. Pharmacological blockade of the DP2 receptor inhibits cigarette smoke-induced inflammation, mucus cell metaplasia, and epithelial hyperplasia in the mouse lung. J Pharmacol Exp Ther 2010;332:764-75.
33. Doukas J, Eide L, Stebbins K, et al. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 (3-(2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl)phenol) as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J Pharmacol Exp Ther 2009;328:758-65.
34. Leclerc O, Lagente V, Planquois JM, et al. Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice. Eur Respir J 2006;27:1102-9.
35. Morris A, Kinnear G, Wan WY, Wyss D, Bahra P, Stevenson CS. Comparison of cigarette smoke-induced acute inflammation in multiple strains of mice and the effect of a matrix metalloproteinase inhibitor on these responses. J Pharmacol Exp Ther 2008;327:851-62.
36. Medicherla S, Fitzgerald MF, Spicer D, et al. p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation. J Pharmacol Exp Ther 2008;324:921-9.
37. Martorana PA, Beume R, Lucattelli M, Wollin L, Lungarella G. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 2005;172:848-53.
38. Martorana PA, Lunghi B, Lucattelli M, De Cunto G, Beume R, Lungarella G. Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice. BMC Pulm Med 2008;8:17.
39. D'Hulst A I, Vermaelen KY, Brusselle GG, Joos GF, Pauwels RA. Time course of cigarette smoke-induced pulmonary inflammation in mice. Eur Respir J 2005;26:204-13.
40. Thorley AJ, Tetley TD. Pulmonary epithelium, cigarette smoke, and chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2007;2:409-28.
41. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-53.
42. Majo J, Ghezzo H, Cosio MG. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J 2001;17:946-53.
43. Miotto D, Ruggieri MP, Boschetto P, et al. Interleukin-13 and -4 expression in the central airways of smokers with chronic bronchitis. Eur Respir J 2003;22:602-8.
44. Boutten A, Bonay M, Laribe S, et al. Decreased expression of interleukin 13 in human lung emphysema. Thorax 2004;59:850-4.
45. Atherton HC, Jones G, Danahay H. IL-13-induced changes in the goblet cell density of human bronchial epithelial cell cultures: MAP kinase and phosphatidylinositol 3-kinase regulation. Am J Physiol Lung Cell Mol Physiol 2003;285:L730-9.
46. Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999;103:779-88.
47. Stebbins K, Broadhead AR, Correa LD, et al. Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation. Eur J Pharmacol 2010;638:142-9.
48. Barnes PJ. Alveolar macrophages in chronic obstructive pulmonary disease (COPD). Cell Mol Biol (Noisy-le-grand) 2004;50 Online Pub:OL627-37.
49. Tajima T, Murata T, Aritake K, et al. Lipopolysaccharide induces macrophage migration via prostaglandin D(2) and prostaglandin E(2). J Pharmacol Exp Ther 2008;326:493-501.
50. Grashoff WF, Sont JK, Sterk PJ, et al. Chronic obstructive pulmonary disease: role of bronchiolar mast cells and macrophages. Am J Pathol 1997;15:1785-90.
51. Csanky E, Ruhl R, Scholtz B, Vasko A, Takacs L, Hempel WM. Lipid metabolite levels of prostaglandin D2 and eicosapentaenoic acid recovered from bronchoalveolar lavage fluid correlate with lung function of chronic obstructive pulmonary disease patients and controls. Electrophoresis 2009;30:1228-34.
52. Boehme SA, Franz-Bacon K, Chen EP, Ly TW, Kawakami Y, Bacon KB. Murine bone marrow-derived mast cells express chemoattractant receptor-homologous molecule expressed on T-helper class 2 cells (CRTh2). Int Immunol 2009;21:621-32.
53. D'Armiento JM, Scharf SM, Roth MD, et al. Eosinophil and T cell markers predict functional decline in COPD patients. Respir Res 2009;10:113.
54. Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis 2006;1:39-47.
55. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994;150(6 Pt 1):1646-52.
56. Monneret G, Gravel S, Diamond M, Rokach J, Powell WS. Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 2001;98:1942-8.
57. Uller L, Mathiesen JM, Alenmyr L, et al. Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation. Respir Res 2007;8:16.
58. Ulven T, Receveur JM, Grimstrup M, et al. Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits. J Med Chem 2006;49:6638-41.
59. Nakamura Y, Miyata M, Ohba T, et al. Cigarette smoke extract induces thymic stromal lymphopoietin expression, leading to T(H)2-type immune responses and airway inflammation. J Allergy Clin Immunol. 2008;122:1208-14.
60. Smelter D, Thompson M, Meuchel L, et al. Thymic Stromal Lymphopoietin (TSLP) and Airway Smooth Muscle. FASEB J 2009;23:622-6.
61. Boehme SA, Franz-Bacon K, Chen EP, et al. A small molecule CRTH2 antagonist inhibits FITC-induced allergic cutaneous inflammation. Int Immunol 2009;21:81-93.
62. Boehme SA, Chen EP, Franz-Bacon K, et al. Antagonism of CRTH2 ameliorates chronic epicutaneous sensitization-induced inflammation by multiple mechanisms. Int Immunol. 2009;21:1-17.
63. Churg A, Tai H, Coulthard T, Wang R, Wright JL. Cigarette smoke drives small airway remodeling by induction of growth factors in the airway wall. Am J Respir Crit Care Med 2006;174:1327-34.
64. Wang RD, Wright JL, Churg A. Transforming growth factor-beta1 drives airway remodeling in cigarette smoke-exposed tracheal explants. Am J Respir Cell Mol Biol 2005;33:387-93.
65. Liu Y, Gao W, Zhang D. Effects of cigarette smoke extract on A549 cells and human lung fibroblasts treated with transforming growth factor-beta1 in a coculture system. Clin Exp Med 2009;Epub Nov 19.
66. Ueda S, Asano K, Tomomatsu K, et al. A Role of Prostaglandin D2 and Its Receptor CRTH2 in Bleomycin-Induce Lung Fibrosis Model. Am J Respir Crit Care Med 2009;179(1 Meeting Abstracts):A5662.